These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24011987)

  • 1. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring.
    Bode-Böger SM; Schopp B; Tröger U; Martens-Lobenhoffer J; Kalousis K; Mailänder P
    Int J Antimicrob Agents; 2013 Oct; 42(4):357-60. PubMed ID: 24011987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
    Tröger U; Drust A; Martens-Lobenhoffer J; Tanev I; Braun-Dullaeus RC; Bode-Böger SM
    Int J Antimicrob Agents; 2012 Oct; 40(4):370-2. PubMed ID: 22795654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of parenteral colistin for the treatment of multiresistant Gram-negative organisms in major burn patients in South Korea.
    Cho YS; Yim H; Yang HT; Hur J; Chun W; Kim JH; Lee BC; Seo DK; Park JM; Kim D
    Infection; 2012 Feb; 40(1):27-33. PubMed ID: 21898119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.
    Frazee E; Rule AD; Lieske JC; Kashani KB; Barreto JN; Virk A; Kuper PJ; Dierkhising RA; Leung N
    Am J Kidney Dis; 2017 May; 69(5):658-666. PubMed ID: 28131530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit.
    Ganapathy H; Pal SK; Teare L; Dziewulski P
    Burns; 2010 Jun; 36(4):522-7. PubMed ID: 19864072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
    Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.
    Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT
    J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.
    Dalfino L; Puntillo F; Mosca A; Monno R; Spada ML; Coppolecchia S; Miragliotta G; Bruno F; Brienza N
    Clin Infect Dis; 2012 Jun; 54(12):1720-6. PubMed ID: 22423120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients.
    Markou N; Apostolakos H; Koumoudiou C; Athanasiou M; Koutsoukou A; Alamanos I; Gregorakos L
    Crit Care; 2003 Oct; 7(5):R78-83. PubMed ID: 12974973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No increased acute kidney injury rate through giving an intravenous colistin loading dose in pediatric patients.
    Wacharachaisurapol N; Kawichai S; Chanakul A; Puthanakit T
    Int J Infect Dis; 2021 May; 106():91-97. PubMed ID: 33771669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population.
    Goverman J; Weber JM; Keaney TJ; Sheridan RL
    J Burn Care Res; 2007; 28(3):421-6. PubMed ID: 17438490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
    Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
    Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
    Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy.
    Ozel AS; Ergönül Ö; Korten V
    J Infect Dev Ctries; 2019 Oct; 13(10):877-885. PubMed ID: 32084017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn].
    Zhang JP; Yang XS; Chen J; Peng YZ; Huang YS
    Zhonghua Shao Shang Za Zhi; 2009 Oct; 25(5):372-6. PubMed ID: 19951562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
    Leuppi-Taegtmeyer AB; Decosterd L; Osthoff M; Mueller NJ; Buclin T; Corti N
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity after prolonged (more than four weeks) administration of intravenous colistin.
    Falagas ME; Rizos M; Bliziotis IA; Rellos K; Kasiakou SK; Michalopoulos A
    BMC Infect Dis; 2005 Jan; 5():1. PubMed ID: 15642116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.